Key Highlights

  • Cingulate (NASDAQ:CING) was trading up 24.53% at USD 4.67 on Tuesday, November 17, 2026, in intraday market data, and no company announcement dated that day explains the move.
  • The FDA issued a complete response letter on CTx-1301 on June 1, 2026, citing chemistry, Manufacturing and controls requests and raising no clinical safety or efficacy concerns, according to the company.
  • Cash was about USD 23.2 million at September 30, 2026, up from USD 11.0 million at December 31, 2025, with the quarterly net loss at USD 7.7 million versus USD 7.3 million a year earlier.
  • Management expects to resubmit the application between December 2026 and January 2027, and a Class 1 review has a two-month goal while a Class 2 review has a six-month goal.

A 24.53% Move With No Same-Day Announcement

Cingulate (NASDAQ:CING) was trading up 24.53% at USD 4.67 on Tuesday, November 17, 2026, in intraday market data. Searches of company releases, filings and published coverage found no announcement dated November 17 that explains the jump, so the cause is unconfirmed. The most recent company news was the third-quarter report on November 13, 2026, and published coverage said the shares fell 12.8% on the day of that release, so part of the move may be a rebound, an inference and not a reported cause. Cingulate is a clinical-stage biopharmaceutical company developing CTx-1301, a dexmethylphenidate tablet for attention Deficit hyperactivity disorder (ADHD).

The Complete Response Letter and the Path to Resubmission

The FDA had a target action date of May 31, 2026, for the new drug application, and it issued a complete response letter on June 1, 2026, according to the company. The letter asked for more chemistry, manufacturing and controls information and, per the company, raised no clinical safety or efficacy concerns. Cingulate said it and its contract manufacturer have substantially completed the manufacturing work, and it expects to resubmit between December 2026 and January 2027, possibly sooner. If the FDA classifies the resubmission as Class 1, the review goal is two months; Class 2 carries a six-month goal. Cingulate (NASDAQ:CING) has said a launch could begin in the third quarter of 2027 if the drug is approved, a company timeline that depends on the FDA review.

Cash, Dilution and the Cost of a Longer Wait

Cingulate (NASDAQ:CING) reported a third-quarter net loss of USD 7.7 million against USD 7.3 million a year earlier, and a nine-month net loss of USD 22.9 million against USD 16.2 million. Selling, general and administrative expense rose 45.5% to USD 4.6 million on commercial readiness spending, while Research and Development was USD 2.9 million, up 2.2%. Cash of about USD 23.2 million at September 30, 2026, supports operations into mid-2027, the company says, after a USD 12.0 million private Placement in the first quarter and USD 22.5 million raised year to date through an at-the-market agreement and a purchase agreement with Lincoln Park Capital. Those programs sell new shares, which dilutes holders. For a stock this small, a small number of trades can move the price, spreads can be wide and quoted moves can reverse.

Where Things Stand

A single-day jump of 24.53% has no confirmed trigger, so the honest answer is that the cause is not known. Cingulate (NASDAQ:CING) still has a manufacturing-related complete response letter to resolve, an application due for resubmission by January 2027 and about USD 23.2 million of cash against a quarterly loss of USD 7.7 million. The next markers are the resubmission itself, the FDA's classification as Class 1 or Class 2, any further financing under the at-the-market and Lincoln Park programs, and whether the price holds after a move that no company news explains.